Young people suffering from peanut allergies have been dealt a significant setback following the announcement that Palforzia, the sole licensed drug designed to reduce the risk of life-threatening reactions, will be pulled from global markets. Manufacturer Stallergenes Greer confirmed the decision to discontinue worldwide production, asserting that the move is not linked to safety concerns but rather a strategic review.

Palforzia, an immune system treatment, works by gradually exposing peanut allergy sufferers to increasing doses of pharmaceutical-grade peanut flour. This process effectively retrains the immune system, leading to desensitization and a reduced risk of severe reactions like anaphylaxis, the most dangerous form of allergic response. Patients are required to take the medication daily and attend regular medical appointments for monitoring. While still advised to avoid peanuts, the treatment significantly mitigates the danger posed by even trace amounts of the allergen.

The discontinuation has been described as 'worrying' and 'upsetting' for families by the allergy charity Anaphylaxis UK, which highlighted that there are currently no other licensed immunotherapy treatment options for peanut allergy. Without Palforzia, children diagnosed with the condition must revert to strict peanut avoidance and consistently carry their emergency medication and allergy action plans.

Initially developed by Aimmune Therapeutics, Palforzia was acquired by Nestlé in 2020 for a reported £2.1 billion, only to be sold to Stallergenes Greer in 2023. At the time of the latter sale, the drug was reportedly considered 'a commercial flop' due to lower-than-expected uptake among healthcare providers. Stallergenes Greer's spokesperson elaborated that while the product demonstrated strong clinical efficacy and safety, its 'complex administrative and dosing requirements have contributed to limited adoption in clinical practice'.

A 'wind down period' has been agreed upon, allowing existing patients to continue treatment, but no new patients are advised to start on the drug after April 1. Palforzia received approval for NHS use in 2021, a year after gaining the green light from the US Food and Drug Administration (FDA).

Peanut allergy affects approximately one in 50 children, translating to about 240,000 in the UK and one million in the US, making it one of the most common food allergies. While about one in five children may outgrow the condition, for the majority, it is a lifelong challenge. The severity varies, but exposure to even tiny quantities of peanut can be rapidly fatal without immediate emergency treatment, as tragically exemplified by cases such as James Atkinson (2020) and Hannah Glass (2023), both of whom died from anaphylaxis after accidental peanut consumption.

Anaphylaxis UK called the decision 'a setback for the allergy community' but offered a glimmer of hope, noting that 'extensive research into allergy treatments is ongoing.' The charity specifically mentioned significant progress in real-food immunotherapy, with the aim of making these treatments safer, more effective, and more widely available through the NHS in the future. They advised current Palforzia patients to continue their prescribed dose and consult their allergy team with any concerns, strongly cautioning against attempting to create homemade versions of the treatment using standard peanut flour, as Palforzia is a pharmaceutical-grade product manufactured to strict standards, including screening for contaminants like fungus.

Stallergenes Greer affirmed its commitment to advancing innovative solutions in allergen immunotherapy, including food allergy treatments, and stated that the experience gained from Palforzia will inform future research and development efforts focused on practical, patient-centered options.